Long-Acting Injectable Buprenorphine enduring module is a recording from the live Regularly Scheduled Series dated October 12, 2023. If you claimed credit for this session at the live meeting, you should not claim credit for this module.

Faculty

Needs Statement

Individuals with OUD need more treatment options that can address problems such as: nonadherence, medication misuse/diversion/theft, access to care, and transportation limitations. Injectable monthly buprenorphine may help address several of the limitations associated with transmucosal buprenorphine. Healthcare providers, social workers, and others involved in the care of individuals with OUD need to be familiar with injectable monthly buprenorphine, the unique requirements for obtaining and administering it, and the REMS requirements to ensure its efficacy and patient safety. 

Target Audience

Physicians, Nurses, Nurse Practitioners, Physician Assistants, Pharmacists, Social Workers

Objectives

Upon completion of this activity, participants will be able to:

1. Explain the fundamental pharmacology of long-acting injectable buprenorphine (LAI-B) formulations. 
2. Identify three potential advantages of LAI-B 
3. Demonstrate the process of initiating and maintaining weekly and monthly formulations in patients, whether they are new to buprenorphine treatment or currently using sublingual (SL) buprenorphine.  
4. Identify common side effects associated with LAI-B formulations. 

Accreditation

In support of improving patient care, University of Kentucky HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CME
This enduring material is designated for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

This training has been approved by the KBML as meeting the statutory requirements of HB1. 1023-H1.5-UKHC/Oct23 

IPE Competencies

• Values/Ethics for Interprofessional Practice
• Roles/ Responsibilities
• Interprofessional Communication
• Teams and Teamwork

CPE
This knowledge-based activity will award 1.25 contact hours (0.125 CEUs) of continuing pharmacy education credit in states that recognize ACPE providers.

ASWB ACE
As a Jointly Accredited Organization, UK HealthCare CECentral is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. UK HealthCare CECentral maintains responsibility for this course. Social workers completing this course receive 1.25 clinical continuing education credits.

CNE
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.25 nursing contact hours.

Faculty Disclosure

All planners, faculty, and others in control of educational content are required to disclose all their financial relationships with ineligible companies within the prior 24 months. An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if the educational content an individual can control is related to the business lines or products of the ineligible company.

None of the planners, faculty, and others in control of educational content for this educational activity have a relevant financial relationship(s) to disclose with ineligible companies.

The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include a discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off-label uses.

Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation

Acknowledgement

In collaboration with UK Substance Use Research Priority Area.